- Companies
- Lumos Diagnostics Holdings
Lumos Diagnostics Holdings Valuation Multiples
Lumos Diagnostics Holdings is valued at $40M as of November 2026, a 2.1x revenue multiple. In the last 12 months, Lumos Diagnostics Holdings revenue was $16M and Lumos Diagnostics Holdings EBITDA was ($6M).
Lumos Diagnostics Holdings Overview
About Lumos Diagnostics Holdings
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
Founded
2018
HQ
Employees
110
Website
Financials (LTM)
EV
$32M
Valuation Multiples
Start free trialLumos Diagnostics Holdings Financials
Lumos Diagnostics Holdings reported last 12-month revenue of $16M and negative EBITDA of ($6M).
In the same LTM period, Lumos Diagnostics Holdings generated $9M in gross profit, ($6M) in EBITDA losses, and had net loss of ($7M).
Revenue (LTM)
Lumos Diagnostics Holdings P&L
In the most recent fiscal year, Lumos Diagnostics Holdings reported revenue of $13M and EBITDA of ($412K).
Lumos Diagnostics Holdings is unprofitable as of last fiscal year, with gross margin of 60%, EBITDA margin of (3%), and net margin of (38%).
Financial data powered by Morningstar, Inc.
Lumos Diagnostics Holdings Stock Performance
Lumos Diagnostics Holdings has current market cap of $40M, and enterprise value of $32M.
Market Cap Evolution
Lumos Diagnostics Holdings' stock price is $0.04.
Lumos Diagnostics Holdings share price decreased by 5.1% in the last 30 days, and by 71.5% in the last year.
Lumos Diagnostics Holdings has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32M | $40M | -5.1% | -5.1% | -46.8% | -71.5% | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLumos Diagnostics Holdings Valuation Multiples
Lumos Diagnostics Holdings trades at 2.1x EV/Revenue multiple, and (5.2x) EV/EBITDA.
EV / Revenue (LTM)
Lumos Diagnostics Holdings Financial Valuation Multiples
As of November 3, 2026, Lumos Diagnostics Holdings has market cap of $40M and EV of $32M.
Lumos Diagnostics Holdings has a P/E ratio of (5.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lumos Diagnostics Holdings Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Lumos Diagnostics Holdings Margins & Growth Rates
Lumos Diagnostics Holdings grew revenue by 52% and EBITDA by 1468% in the last fiscal year.
In the most recent fiscal year, Lumos Diagnostics Holdings reported gross margin of 60%, EBITDA margin of (3%), and net margin of (38%).
Lumos Diagnostics Holdings Margins
Lumos Diagnostics Holdings Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Lumos Diagnostics Holdings Operational KPIs
Lumos Diagnostics Holdings' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Lumos Diagnostics Holdings Competitors
Lumos Diagnostics Holdings competitors include Harvard Bioscience, OssDsign, Xtant Medical, Carclo, Oncosem, SMAIO, Cyclopharm, Davion Healthcare, Cryosite and BrainCool.
Most Lumos Diagnostics Holdings public comparables operate across Medical Devices, Diagnostics & Genomics, BioTech and DeepTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $87M | ($47M) | 0.9x | 0.9x | (1.7x) | 9.1x | |||
| $18M | ($5M) | 1.2x | 1.4x | (4.7x) | (4.8x) | |||
| $134M | $16M | 0.4x | 0.5x | 3.5x | (20.1x) | |||
| $153M | $24M | 0.5x | 0.5x | 3.0x | 2.9x | |||
| $14M | $3M | 3.0x | - | 13.5x | - | |||
| $10M | ($1M) | 3.5x | 3.3x | (33.2x) | (16.7x) | |||
| $12M | ($11M) | 2.9x | 1.3x | (3.1x) | (3.3x) | |||
| - | ($922K) | - | - | (46.7x) | - | |||
This data is available for Pro users. Sign up to see all Lumos Diagnostics Holdings competitors and their valuation data. Start Free Trial | ||||||||
Lumos Diagnostics Holdings VC Funding History
Before going public, Lumos Diagnostics Holdings raised $40M in total equity funding, across 3 rounds.
Lumos Diagnostics Holdings Funding Rounds
Acquisitions by Lumos Diagnostics Holdings
Lumos Diagnostics Holdings has acquired 1 company to date.
Last acquisition by Lumos Diagnostics Holdings was on May 29th 2019. Lumos Diagnostics Holdings acquired Rapid Pathogen Screening for undisclosed valuation.
Latest Acquisitions by Lumos Diagnostics Holdings
| Description | Rapid Pathogen Screening is a developer and marketer of point-of-care diagnostic tests for infectious diseases. Florida-headquartered, the company produces rapid tests for conjunctivitis pathogens like adenovirus and Streptococcus, deliverable in 10 minutes without lab equipment. Its patented platform also supports U.S. government contracts for biothreat and nerve agent detection. Founded in 2004, Rapid Pathogen Screening targets clinician offices with high-sensitivity assays for inflammatory conditions. |
| HQ Country | |
| HQ City | Sarasota, FL |
| Deal Date | 29 May 2019 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Lumos Diagnostics Holdings acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lumos Diagnostics Holdings
| When was Lumos Diagnostics Holdings founded? | Lumos Diagnostics Holdings was founded in 2018. |
| Where is Lumos Diagnostics Holdings headquartered? | Lumos Diagnostics Holdings is headquartered in United States. |
| How many employees does Lumos Diagnostics Holdings have? | As of today, Lumos Diagnostics Holdings has over 110 employees. |
| Is Lumos Diagnostics Holdings publicly listed? | Yes, Lumos Diagnostics Holdings is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Lumos Diagnostics Holdings? | Lumos Diagnostics Holdings trades under LDX ticker. |
| When did Lumos Diagnostics Holdings go public? | Lumos Diagnostics Holdings went public in 2021. |
| Who are competitors of Lumos Diagnostics Holdings? | Lumos Diagnostics Holdings main competitors include Harvard Bioscience, OssDsign, Xtant Medical, Carclo, Oncosem, SMAIO, Cyclopharm, Davion Healthcare, Cryosite, BrainCool. |
| What is the current market cap of Lumos Diagnostics Holdings? | Lumos Diagnostics Holdings' current market cap is $40M. |
| What is the current revenue of Lumos Diagnostics Holdings? | Lumos Diagnostics Holdings' last 12 months revenue is $16M. |
| What is the current revenue growth of Lumos Diagnostics Holdings? | Lumos Diagnostics Holdings revenue growth (NTM/LTM) is 54%. |
| What is the current EV/Revenue multiple of Lumos Diagnostics Holdings? | Current revenue multiple of Lumos Diagnostics Holdings is 2.1x. |
| Is Lumos Diagnostics Holdings profitable? | No, Lumos Diagnostics Holdings is not profitable. |
| What is the current EBITDA of Lumos Diagnostics Holdings? | Lumos Diagnostics Holdings has negative EBITDA and is not profitable. |
| What is Lumos Diagnostics Holdings' EBITDA margin? | Lumos Diagnostics Holdings' last 12 months EBITDA margin is (39%). |
| What is the current EV/EBITDA multiple of Lumos Diagnostics Holdings? | Current EBITDA multiple of Lumos Diagnostics Holdings is (5.2x). |
| What is the current FCF of Lumos Diagnostics Holdings? | Lumos Diagnostics Holdings' last 12 months FCF is ($6M). |
| What is Lumos Diagnostics Holdings' FCF margin? | Lumos Diagnostics Holdings' last 12 months FCF margin is (41%). |
| What is the current EV/FCF multiple of Lumos Diagnostics Holdings? | Current FCF multiple of Lumos Diagnostics Holdings is (5.0x). |
| How many companies Lumos Diagnostics Holdings has acquired to date? | As of November 2026, Lumos Diagnostics Holdings has acquired 1 company. |
| What was the largest acquisition by Lumos Diagnostics Holdings? | None of the M&A deals Lumos Diagnostics Holdings has completed have disclosed valuations. |
| What companies Lumos Diagnostics Holdings acquired? | Lumos Diagnostics Holdings acquired Rapid Pathogen Screening. |
| In how many companies Lumos Diagnostics Holdings has invested to date? | Lumos Diagnostics Holdings hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Lumos Diagnostics Holdings
Lists including Lumos Diagnostics Holdings
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




